Table 1.

Overview of candidate genomic technologies under consideration

Candidate technology	Purpose
EGFR mutation testing for erlotinib maintenance therapy after first-line chemotherapy in advanced NSCLC	Disease prognosis and identification of the patients with mutations that are most likely to benefit with erlotinib maintenance therapy
ERCC1 expression testing for platinum-based adjuvant therapy in resected early-stage NSCLC	Disease prognosis and identification of ERCC1-negative patients who are most likely to benefit from platinum-based adjuvant chemotherapy
BRAF mutation testing in colorectal cancer to inform use of cetuximab and panitumumab	Disease prognosis and identification of patients with mutations that are good candidates for therapy with cetuximab and panitumumab
EGFR gene copy number (FISH) testing to inform cetuximab therapy in advanced NSCLC	Disease prognosis and identification of patients who are FISH positive and most likely to respond to chemotherapy + cetuximab
Gene expression profiling in multiple myeloma to identify high-risk patients for more aggressive therapy	Disease prognosis and identification of patients with high-risk profiles for treatment with bortezomib
CEA, CA 15-3, and CA27.29 marker testing to detect recurrence after primary breast cancer therapy	Prognostic for recurrence of breast cancer and can lead to earlier treatment of recurrence

EGFR, epidermal growth factor receptor; ERCC1, excision repair cross complementation 1; FISH, fluorescence in situ hybridization; NSCLC, non-small-cell lung cancer.